<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731352</url>
  </required_header>
  <id_info>
    <org_study_id>Ahead-T301</org_study_id>
    <nct_id>NCT02731352</nct_id>
  </id_info>
  <brief_title>Study of Apatinib in Patients With Differentiated Thyroid Cancer</brief_title>
  <official_title>Study of Apatinib in Patients With Local Advanced/Metastatic Iodine-131（131I）-Refractory/Resistant Differentiated Thyroid Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of apatinib in locally&#xD;
      advanced/metastatic radioactive iodine-refractory/resistant differentiated thyroid cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 11, 2016</start_date>
  <completion_date type="Actual">February 28, 2021</completion_date>
  <primary_completion_date type="Actual">February 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>An expected average of 8 weeks</time_frame>
    <description>Disease control rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>An expected average of 8 weeks</time_frame>
    <description>Objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>Up to approximately 43 months</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 48 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>iodine-131 Refractory/Resistant Differentiated Thyroid Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>iodine-131 (131I) -Refractory/Resistant Differentiated Thyroid Cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib Mesylate Tablets 750 mg q.d p.o. in 1-10 cases of differentiated thyroid cancer subjects.</description>
    <arm_group_label>iodine-131 Refractory/Resistant Differentiated Thyroid Cancer</arm_group_label>
    <other_name>Apatinib 750mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>Apatinib Mesylate Tablets 500 mg q.d. p.o. in 11-20 cases of differentiated thyroid cancer subjects.</description>
    <arm_group_label>iodine-131 Refractory/Resistant Differentiated Thyroid Cancer</arm_group_label>
    <other_name>Apatinib 500mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Locally advanced or metastatic differentiated thyroid cancer (papillary, follicular,&#xD;
             Hurthle cells, poorly differentiated carcinoma). At least one measurable lesion&#xD;
             (helical CT scan long diameter ≥10mm, meet the requirements of the standard Response&#xD;
             Evaluation Criteria In Solid Tumors（RESCIST） version 1.1);&#xD;
&#xD;
          2. Disease progression within 14 months before inclusion;&#xD;
&#xD;
          3. Subjects must be 131I-refractory / resistant as defined by at least one of the&#xD;
             following;&#xD;
&#xD;
               -  Lesions that do not demonstrate iodine uptake on any radioiodine scan&#xD;
&#xD;
               -  Subjects received a single radioactive iodine therapy within 12 months (≥ 3.7&#xD;
                  Giga Becquerel (GBq) [≥ 100 millicurie (mCi) ]) and target lesion disease&#xD;
                  progression&#xD;
&#xD;
               -  Every two radioactive iodine treatment interval &lt;12 months, doses ≥ 3.7 GBq [≥100&#xD;
                  mCi], disease progress more than 12 months after at least once iodine therapy;&#xD;
&#xD;
               -  Received a total dose of radioactive iodine therapy ≥ 22.2 GBq (≥ 600 mCi)&#xD;
&#xD;
          4. main organs function is normal;&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group（ECOG）Performance Status（PS） :0-2;&#xD;
&#xD;
          6. An expected survival of ≥ 3 months;&#xD;
&#xD;
          7. Pregnancy test (serum or urine) has to be performed for woman of childbearing age&#xD;
             within 7 days before enrolment and the test result must be negative. They shall take&#xD;
             appropriate methods for contraception during the study until the 8th week post the&#xD;
             last administration of study drug. For men, (previous surgical sterilization&#xD;
             accepted), shall agree to take appropriate methods of contraception during the study&#xD;
             until the 8th week post the last administration of study drug;&#xD;
&#xD;
          8. Patient has to voluntarily join the study and sign the Informed Consent Form for the&#xD;
             study;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Other thyroid cancer histological subtypes (such as medullary carcinoma, lymphoma or&#xD;
             sarcoma);&#xD;
&#xD;
          2. Received VEGFR inhibitor treatment within 1 month;&#xD;
&#xD;
          3. Subjects with poor-controlled arterial hypertension (systolic blood pressure&gt; 140 mmHg&#xD;
             and diastolic blood pressure &gt; 90 mm Hg) despite standard medical management; Coronary&#xD;
             heart disease greater than ClassII; II-level arrhythmia (including QT interval&#xD;
             prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class II cardiac&#xD;
             dysfunction;&#xD;
&#xD;
          4. Factors that could have an effect on oral medication (such as inability to swallow,&#xD;
             chronic diarrhea and intestinal obstruction);&#xD;
&#xD;
          5. Subjects with high gastrointestinal bleeding risk, including the following conditions:&#xD;
             local active ulcer lesions with positive fecal occult blood test (++); history of&#xD;
             black stool, or vomiting blood in the past 3 months;&#xD;
&#xD;
          6. Abnormal Coagulation (INR&gt;1.5、APTT&gt;1.5 UNL), with tendency of bleed;&#xD;
&#xD;
          7. Received anti-thyroid cancer chemotherapy treatment (allows the use of low-dose&#xD;
             chemotherapy with radiation sensitizer) or thalidomide(or derivative) therapy;&#xD;
&#xD;
          8. Pregnant or lactating women;&#xD;
&#xD;
          9. Other conditions regimented at investigators' discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Peking</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Yansong Lin</investigator_full_name>
    <investigator_title>Prof. M.D.</investigator_title>
  </responsible_party>
  <keyword>apatinib</keyword>
  <keyword>Iodine-131</keyword>
  <keyword>Differentiated Thyroid Cancer</keyword>
  <keyword>refractory</keyword>
  <keyword>resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

